keyword
MENU ▼
Read by QxMD icon Read
search

Gattex

keyword
https://www.readbyqxmd.com/read/27433811/safety-and-efficacy-of-teduglutide-gattex-in-patients-with-crohn-s-disease-and-need-for-parenteral-support-due-to-short-bowel-syndrome-associated-intestinal-failure
#1
Bharati Kochar, Millie D Long, Edward Shelton, Lorraine Young, Francis A Farraye, Vijay Yajnik, Hans Herfarth
BACKGROUND: Teduglutide is a GLP-2 analogue indicated for treatment of adults with short bowel syndrome (SBS). Because of the rarity of SBS, real-world safety or efficacy data are not available in patients with Crohn's disease (CD) and SBS treated with teduglutide. AIM: To evaluate teduglutide's safety and efficacy in CD patients with SBS. METHODS: We conducted a retrospective cohort study at 3 tertiary centers in the United States between 2012 and 2014...
July 18, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/25883117/teduglutide-for-safe-reduction-of-parenteral-nutrient-and-or-fluid-requirements-in-adults-a-systematic-review
#2
Jane K Naberhuis, Kelly A Tappenden
BACKGROUND: Teduglutide (Gattex; NPS Pharma, Bedminster, NJ), a recombinant analogue of human glucagon-like peptide 2 (GLP-2), is the first long-term medical therapy approved for the treatment of adults dependent on parenteral nutrition (PN). OBJECTIVE: To assess the efficacy and safety of teduglutide in reducing PN (parenteral nutrient and/or fluid) requirements in PN-dependent adults. METHODS: Studies were identified using predefined search criteria and multiple databases, including Medline and Embase...
November 2016: JPEN. Journal of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/25859983/teduglutide-a-guide-to-its-use-in-short-bowel-syndrome
#3
REVIEW
Kate McKeage
Teduglutide (Gattex(®)) is a recombinant analogue of human glucagon-like peptide-2 and is indicated for the treatment of adults with short bowel syndrome (SBS) dependent on parenteral support (PS). In a pivotal, 24-week clinical trial in SBS patients, subcutaneous teduglutide 0.05 mg/kg once daily increased absorption from the remnant intestine as evidenced by significant reductions in PS volume requirements versus placebo. Improvements attained in absorption in the first 6 months of therapy were maintained during the extension trial (total teduglutide treatment periods of up to 30 months), with evidence indicating that benefits accrue over time...
May 2015: Clinical Drug Investigation
https://www.readbyqxmd.com/read/25485516/gut-hormones-in-the-treatment-of-short-bowel-syndrome-and-intestinal-failure
#4
REVIEW
Palle B Jeppesen
PURPOSE OF REVIEW: The approval of teduglutide, a recombinant analog of human glucagon-like peptide (GLP) 2, by the US Food and Drug Administration (Gattex) and the European Medicines Agency (Revestive) has illustrated the potential of selected gut hormones as treatments in patients with short-bowel syndrome and intestinal failure. Gut hormones may improve the structural and functional intestinal adaptation following intestinal resection by decreasing a rapid gastric emptying and hypersecretion, by increasing the intestinal blood flow, and by promoting intestinal growth...
February 2015: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/24406477/new-approaches-to-the-treatments-of-short-bowel-syndrome-associated-intestinal-failure
#5
REVIEW
Palle B Jeppesen
PURPOSE OF REVIEW: Teduglutide, a recombinant analog of human glucagon-like peptide 2, has recently been approved in the US and Europe (Gattex and Revestive, respectively) as the first targeted treatment of short bowel syndrome-associated intestinal failure (SBS-IF). Glucagon-like peptide 2 improves structural and functional intestinal adaptation following intestinal resection by decelerating a rapid gastric emptying, by decreasing gastric hypersecretion, by increasing intestinal blood flow and by promoting intestinal growth...
March 2014: Current Opinion in Gastroenterology
https://www.readbyqxmd.com/read/23729002/teduglutide-a-review-of-its-use-in-the-treatment-of-patients-with-short-bowel-syndrome
#6
REVIEW
Celeste B Burness, Paul L McCormack
The recombinant analogue of human glucagon-like peptide-2 (GLP-2) teduglutide (Gattex(®), Revestive(®)) is a novel therapy for short bowel syndrome (SBS). GLP-2 is a naturally occurring hormone that regulates the growth, proliferation and maintenance of cells lining the gastrointestinal tract. Subcutaneous teduglutide is the first long-term medical therapy approved for the treatment of adult patients with SBS who are dependent on parenteral support (parenteral nutrition and/or intravenous fluids). In a pivotal, double-blind, multicentre, phase III study in adult patients with SBS who were dependent on parenteral support, a significantly higher proportion of teduglutide 0...
June 2013: Drugs
https://www.readbyqxmd.com/read/23588102/teduglutide-injection-gattex-for-short-bowel-syndrome
#7
(no author information available yet)
No abstract text is available yet for this article.
April 15, 2013: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/22016579/emerging-treatment-options-for-short-bowel-syndrome-potential-role-of-teduglutide
#8
Cheng T Tee, Katharina Wallis, Simon M Gabe
INTRODUCTION: Current medical management of short bowel syndrome (SBS) involves the use of lifelong parenteral nutrition (PN). Glucagon-like peptide-2 (GLP-2), an important intestinotrophic growth factor has been shown to increase intestinal absorption in SBS through augmentation of post-resection intestinal adaptation. This may lead to the reduction of PN dependence in patients with SBS. AREAS COVERED IN REVIEW: Advancing research of GLP-2 physiology has spurred the growing understanding of the diverse effects of GLP-2...
2011: Clinical and Experimental Gastroenterology
https://www.readbyqxmd.com/read/19474717/short-bowel-syndrome-the-role-of-glp-2-on-improving-outcome
#9
REVIEW
Katharina Wallis, Julian R F Walters, Simon Gabe
PURPOSE OF REVIEW: The medical management of short bowel syndrome frequently requires lifelong parenteral nutrition. Methods of increasing intestinal absorption and reducing parenteral nutrition dependence, by improving postresection intestinal adaptation, are increasingly being explored. Glucagon-like peptide-2 (GLP-2) is an important intestinotrophic growth factor and mediator of intestinal adaptation. This review summarizes our current understanding of GLP-2 physiology and provides an update on clinical trials in short bowel syndrome and related conditions...
September 2009: Current Opinion in Clinical Nutrition and Metabolic Care
https://www.readbyqxmd.com/read/18491995/teduglutide-in-intestinal-adaptation-and-repair-light-at-the-end-of-the-tunnel
#10
REVIEW
Houssam E Mardini, Willem J S de Villiers
BACKGROUND: Malabsorption of nutrients, fluids and electrolytes is a key finding in patients with short bowel syndrome. If not compensated for by increased intake, it leads to diminished body stores and subclinical, and eventually clinical, deficiencies. Until recently, management options were limited to interventions aimed at provision of adequate macro- and micronutrients and fluids to prevent malnutrition, nutrient deficiencies and dehydration, treatment of associated infections and correction and prevention of acid-base disturbances...
June 2008: Expert Opinion on Investigational Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"